Merck layoffs create opportunity for biotech startups. Learn how GenePioneer attracts top talent, offering equity & growth in 2026.
Chase Tate
·
Agrobio startups face ethical challenges with gene editing. Learn how transparency builds public trust and ensures long-term success by 2026.
·
Startup funding is drying up. Learn why PPI pressures are hitting capital raising, how valuations dropped 25%, and what founders must do now.
·
Founders: Understand 2025 cap table dilution risks from complex notes. Model scenarios to protect equity, control. 0.5% difference is $100k+.
·
CRISPR gene-editing in agriculture is set for $50B+ investment by 2030. Learn why it matters for crops, food, and future growth opportunities.
·
·
8 min read
How tech rebuilds war-torn regions. See how digital aid, mobile payments, and AI help restore stability and peace by 2027.
·
·
7 min read
Goldstar's new product owner role signals a key 2026 digital shift. Learn why this move prioritizes customers and accountability over old methods.
·
·
6 min read
Cyberattacks on global trade rose 15% in 2025. Learn how MFA and ZTNA can cut risk by 90% and protect your supply chain.
·
·
9 min read
Pharma startups face 2026 compliance demands. Learn why proactive regulatory strategy, allocating 15% R&D budget, and eCTD 4.0 are critical.
·
·
7 min read
Is AbbVie's aggressive biotech partnership model sustainable? Learn how its focus on late-stage assets, like Cerevel Therapeutics, shapes its future.
·
·
6 min read
